Welcome to Unicycive, a brand with a unified mindset to transform healthcare and make a monumental impact on patients' lives. We are more than just individuals; we are a team driven by a shared goal. Led by our CEO, Shalabh Gupta, Unicycive was created to deliver game-changing solutions for the most underserved patients worldwide.

Our therapeutic focus is on addressing major global health issues with pressing unmet medical needs, primarily kidney diseases and beyond. We follow a uniform approach, utilizing our meticulously designed biotech system and end-to-end mining process to efficiently deliver disease-modifying therapies. In our pipeline, we have the unique opportunity to develop groundbreaking treatments, including Uni-494, which targets acute kidney injury/impairment (AKI), and Renazorb - a nanoparticle technology-based therapy showing therapeutic promise in hyperphosphatemia.

As we progress in our mission, we remain committed to keeping our shareholders and potential investors informed through regular news updates. We believe that mitochondria plays a critical role in various diseases and are dedicated to bringing innovative solutions to the market. We also prioritize patient support and resources, aiming to make a meaningful difference in their lives.

Visit our website for valuable information and guidance on navigating renal diseases. Join us on this extraordinary journey as we revolutionize healthcare for the better. Together, we can build a brighter future